PL328127A1 - Methods of inhibiting aponeurotic muscular fibromatosis - Google Patents

Methods of inhibiting aponeurotic muscular fibromatosis

Info

Publication number
PL328127A1
PL328127A1 PL97328127A PL32812797A PL328127A1 PL 328127 A1 PL328127 A1 PL 328127A1 PL 97328127 A PL97328127 A PL 97328127A PL 32812797 A PL32812797 A PL 32812797A PL 328127 A1 PL328127 A1 PL 328127A1
Authority
PL
Poland
Prior art keywords
aponeurotic
fibromatosis
muscular
inhibiting
methods
Prior art date
Application number
PL97328127A
Inventor
Maria Luisa Brandi
Francesco Tonelli
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9603148.9A external-priority patent/GB9603148D0/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PL328127A1 publication Critical patent/PL328127A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
PL97328127A 1996-01-29 1997-01-27 Methods of inhibiting aponeurotic muscular fibromatosis PL328127A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1077396P 1996-01-29 1996-01-29
GBGB9603148.9A GB9603148D0 (en) 1996-02-15 1996-02-15 Methods of inhibiting musculoaponeurotic fibromatoses (desmoid tumors)

Publications (1)

Publication Number Publication Date
PL328127A1 true PL328127A1 (en) 1999-01-18

Family

ID=26308707

Family Applications (1)

Application Number Title Priority Date Filing Date
PL97328127A PL328127A1 (en) 1996-01-29 1997-01-27 Methods of inhibiting aponeurotic muscular fibromatosis

Country Status (11)

Country Link
EP (1) EP0907361A4 (en)
JP (1) JP2000503995A (en)
KR (1) KR19990082055A (en)
CN (1) CN1209746A (en)
AU (1) AU707675B2 (en)
CZ (1) CZ235398A3 (en)
EA (1) EA199800678A1 (en)
IL (1) IL125523A0 (en)
NO (1) NO983452L (en)
PL (1) PL328127A1 (en)
WO (1) WO1997026878A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2135195C1 (en) * 1998-12-17 1999-08-27 Овсюк Валерий Григорьевич Method for producing material containing prostate cells and treating the cases of uterine fibromatosis, chronic prostatitis and male sexual function disorders by applying transplantation method
AU781168B2 (en) 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5552162A (en) * 1993-02-09 1996-09-03 Arch Development Corporation Method for improvement of scar size and appearance
US5457116A (en) * 1993-10-15 1995-10-10 Eli Lilly And Company Methods of inhibiting uterine fibrosis
CA2118096A1 (en) * 1993-10-15 1995-04-16 Srinivasan Chandrasekhar Methods for treating resistant neoplasms
US5574047A (en) * 1993-12-21 1996-11-12 Eli Lilly And Company Methods of inhibiting imperfect tissue repair

Also Published As

Publication number Publication date
NO983452D0 (en) 1998-07-27
KR19990082055A (en) 1999-11-15
EP0907361A4 (en) 2002-05-02
WO1997026878A1 (en) 1997-07-31
CN1209746A (en) 1999-03-03
EA199800678A1 (en) 1999-02-25
NO983452L (en) 1998-07-27
JP2000503995A (en) 2000-04-04
AU2124097A (en) 1997-08-20
CZ235398A3 (en) 1999-02-17
AU707675B2 (en) 1999-07-15
IL125523A0 (en) 1999-03-12
EP0907361A1 (en) 1999-04-14

Similar Documents

Publication Publication Date Title
GB2299592B (en) Knitted covers
GB9526560D0 (en) Use of 2-Amino-Heterocycles
EP0851759A4 (en) Compounds and methods
IL118483A0 (en) Methods for inhibiting vascular smooth muscle cell migration
IL112051A0 (en) Methods of inhibiting sexual precocity
IL118574A0 (en) Methods of inhibiting melanoma
PL331766A1 (en) Method of inhibiting fas expression
ZA96725B (en) Use of phenyclyclohexylcarboxamides
PL328127A1 (en) Methods of inhibiting aponeurotic muscular fibromatosis
IL125522A0 (en) Methods of increasing sphincter competence
EP0868913A4 (en) Intimal thickening inhibitor
GB9510563D0 (en) Well inhibition
SG64924A1 (en) Inhibiting photodecompostion of 3-substituted-2- oxindoles
GB9418826D0 (en) Method of piling
TW324224U (en) Improved structure of a dumbbell
PL309903A1 (en) Method of obtaining chloroderivatives of aromatic nitroanilins
AU119949S (en) Deep oval bowl
GB9525170D0 (en) Bath net
TW312335U (en) Improved structure of step trainer
GB9520546D0 (en) Rockerway bath
TW297480U (en) Improved structure of faucet
GB9512063D0 (en) Divot keeper
ZA962440B (en) Destressing of railtracks
TW325699U (en) Improved structure of exerciser
GB9502649D0 (en) Geogrids